Tvardi Therapeutics, Inc. (TVRD)
(Delayed Data from NSDQ)
$7.00 USD
+0.31 (4.63%)
Updated Oct 14, 2025 04:00 PM ET
After-Market: $6.90 -0.10 (-1.43%) 5:18 PM ET
3-Hold of 5 3
F Value A Growth A Momentum C VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
TVRD 7.00 +0.31(4.63%)
Will TVRD be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for TVRD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TVRD
TVRD Stock Plunges 84% After Phase II Fibrosis Study Misses Key Goals
TVRD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for TVRD
Tivardi downgraded at Raymond James following TTI-101 trial failure
Tvardi Therapeutics (TVRD) Downgraded by Raymond James | TVRD Stock News
Is TVRD poised for gains? Slingshot Bullish shows up after crashing 83.92%
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Tvardi downgraded to Market Perform from Outperform at Raymond James